About Bottneuro: At Bottneuro, we are pioneering the future of personalized neurological care with a strong focus on developing cutting-edge solutions for neurodegenerative diseases, particularly Alzheimer's disease. Our mission is to improve the quality of life for patients by leveraging advanced technologies to create innovative, non-invasive treatments that are both effective and accessible. Our Innovation: Bottneuro has developed the Miamind® Neurostimulator, a groundbreaking, patient-specific device designed for transcranial electrical stimulation (tES). This non-invasive, home-based medical device is tailored to the individual needs of patients. By utilizing 3D-printed, custom-made caps based on MRI scans, our device ensures precise stimulation of the brain's cortical regions, enhancing the treatment's effectiveness. Impact on Alzheimer's Care: Recent clinical trials exploring tES at gamma frequencies have demonstrated its potential to influence the pathological progression of Alzheimer's disease. These studies have shown promising results, including enhanced cerebral blood flow, improved critical cognitive functions such as episodic memory, language, orientation, attention, overall cognition, and a reduction in pTau levels. Regulatory Excellence: Our commitment to quality and safety is reflected in our rigorous approach to regulatory compliance. The Miamind® Neurostimulator is registered with Swissmedic and the British regulatory authority as a custom-made device, paving the way for its use in clinical settings across Europe. We are actively pursuing FDA and CE marking to expand our reach globally and ensure that patients around the world can benefit from our innovative treatment. Join Us: We invite neurologists, psychiatrists, researchers, and healthcare providers to join us in our mission to revolutionize neurological care. Together, we can make a profound difference in the lives of millions of patients and their families.